CA2413906A1 - Carboxyalkylether-acat inhibitor combinations - Google Patents

Carboxyalkylether-acat inhibitor combinations Download PDF

Info

Publication number
CA2413906A1
CA2413906A1 CA002413906A CA2413906A CA2413906A1 CA 2413906 A1 CA2413906 A1 CA 2413906A1 CA 002413906 A CA002413906 A CA 002413906A CA 2413906 A CA2413906 A CA 2413906A CA 2413906 A1 CA2413906 A1 CA 2413906A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
phenyl
pharmaceutical composition
acat inhibitor
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002413906A
Other languages
English (en)
French (fr)
Inventor
Bruce Jeffrey Auerbach
Donna Lee Zobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2413906A1 publication Critical patent/CA2413906A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002413906A 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations Abandoned CA2413906A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21005600P 2000-06-07 2000-06-07
US60/210,056 2000-06-07
PCT/US2001/014804 WO2001093845A2 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations

Publications (1)

Publication Number Publication Date
CA2413906A1 true CA2413906A1 (en) 2001-12-13

Family

ID=22781424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002413906A Abandoned CA2413906A1 (en) 2000-06-07 2001-05-08 Carboxyalkylether-acat inhibitor combinations

Country Status (14)

Country Link
EP (1) EP1292363A2 (es)
JP (1) JP2003535125A (es)
AR (1) AR034255A1 (es)
AU (1) AU2001263003A1 (es)
BR (1) BR0111428A (es)
CA (1) CA2413906A1 (es)
GT (1) GT200100106A (es)
MX (1) MXPA02010762A (es)
PA (1) PA8518601A1 (es)
PE (1) PE20020265A1 (es)
SV (1) SV2002000466A (es)
TN (1) TNSN01085A1 (es)
UY (1) UY26752A1 (es)
WO (1) WO2001093845A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387236B2 (en) 2001-10-09 2008-06-17 Delaware Capital Formation, Inc. Dispensing of currency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease

Also Published As

Publication number Publication date
AR034255A1 (es) 2004-02-18
BR0111428A (pt) 2003-06-10
GT200100106A (es) 2002-05-20
AU2001263003A1 (en) 2001-12-17
TNSN01085A1 (en) 2005-11-10
MXPA02010762A (es) 2003-03-10
WO2001093845A3 (en) 2002-10-10
PA8518601A1 (es) 2002-07-30
PE20020265A1 (es) 2002-04-19
WO2001093845A2 (en) 2001-12-13
EP1292363A2 (en) 2003-03-19
JP2003535125A (ja) 2003-11-25
SV2002000466A (es) 2002-04-03
UY26752A1 (es) 2001-07-31

Similar Documents

Publication Publication Date Title
ES2279526T3 (es) Metodo y composicion farmaceutica para regular la concentracion de lipidos.
RU2363458C2 (ru) Комбинированная лекарственная терапия для лечения ожирения
JP2000515526A (ja) Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法
CN110025608A (zh) 降低心血管疾病风险的方法
JPH04225916A (ja) 脂血障害の治療用組成物
JPH04257518A (ja) Ｉｉｉ型高リポ蛋白血症の予防または治療用医薬組成物
JP2006508995A (ja) 血清トリグリセリド値を低下させるためのＰＰＡＲαアゴニスト及びメトホルミンの使用
CA2413906A1 (en) Carboxyalkylether-acat inhibitor combinations
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
US20040072903A1 (en) Carboxyalkylether-acat inhibitors combinations
ES2300750T3 (es) Uso combinado de un fibrato y orlistat para el tratamiento de la obesidad.
JP6454436B1 (ja) ペマフィブラートを含有する医薬
AU2019315823A1 (en) New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
CA2030209A1 (en) Therapeutic agents
JP7418502B2 (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
WO2005112944A1 (ja) 糖尿病の予防または治療のための薬剤
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
JP2006225263A (ja) 腎疾患予防・治療剤
CA2233558C (en) Method and pharmaceutical composition for regulating lipid concentration
US20060293218A1 (en) Salicylate therapeutic compound and process for controlled delivery thereof
WO1994012166A1 (en) Therapeutic agents for the treatment of cachexia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead